Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Oct 16;16(1):1121-1128.
doi: 10.1159/000533999. eCollection 2023 Jan-Dec.

Cystoid Macular Edema following Treatment with Nanoparticle Albumin-Bound Paclitaxel and Atezolizumab for Metastatic Breast Cancer

Hiroaki Yamane  1   2 , Tomoko Itagaki  1 , Keiko Kajitani  1 , Yuji Koura  3 , Yoshiharu Kawabuchi  4 , Masahiro Ohara  1
Affiliations
Case Reports

Cystoid Macular Edema following Treatment with Nanoparticle Albumin-Bound Paclitaxel and Atezolizumab for Metastatic Breast Cancer

Hiroaki Yamane et al. Case Rep Oncol. .

Abstract

Cystoid macular edema (CME) is a rare side effect associated with chemotherapy. Although the development of CME has been reported to occur following treatment with taxane drugs, such as nanoparticle albumin-bound paclitaxel (Nab-PTX), the occurrence of CME with treatment with atezolizumab has not yet been reported. Here, we report the case of a 49-year-old woman who developed CME 19 months into chemotherapy with Nab-PTX and atezolizumab. Improvement was not achieved with steroid injections into the Tenon's sac, and Nab-PTX and atezolizumab treatments were ceased. One month later, there was subjective improvement in her symptoms. Although many reports have indicated that cessation of chemotherapy has successfully improved CME, a specific treatment for CME has not yet been established. Clinicians should be aware of the ophthalmologic side effects and offer immediate treatment if symptoms develop.

Keywords: Atezolizumab; Breast cancer; Cystoid macular edema; Nanoparticle albumin-bound paclitaxel.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Fig. 1.
Fig. 1.
Spectral domain OCT imaging revealing bilateral CME during the initial visit to the ophthalmologist (right side (a), left side (b)). Improvement in the bilateral CME is observed 2 months following cessation of chemotherapy treatment (right side (c), left side (d)).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Iams WT, Porter J, Horn L. Immunotherapeutic approaches for small-cell lung cancer. Nat Rev Clin Oncol. 2020;17(5):300–12. 10.1038/s41571-019-0316-z. - DOI - PMC - PubMed
    1. Rizzo A, Ricci AD, Lanotte L, Lombardi L, Di Federico A, Brandi G, et al. . Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects. Expert Opin Investig Drugs. 2022;31(6):557–65. 10.1080/13543784.2022.2009456. - DOI - PubMed
    1. Garg AD, Dudek-Peric AM, Romano E, Agostinis P. Immunogenic cell death. Int J Dev Biol. 2015;59(1–3):131–40. 10.1387/ijdb.150061pa. - DOI - PubMed
    1. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. . Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–21. 10.1056/NEJMoa1809615. - DOI - PubMed
    1. Noguchi Y, Kawashima Y, Maruyama M, Kawara H, Tokuyama Y, Uchiyama K, et al. . Risk factors for eye disorders caused by paclitaxel: a retrospective study. Biol Pharm Bull. 2018;41(11):1694–700. 10.1248/bpb.b18-00444. - DOI - PubMed

Publication types